Safety and Efficacy of the 2.25-mm Sirolimus-Eluting Bx Velocity Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions: the SIRIUS 2.25 Trial

MLA

Moses, Jeffrey W., et al. “Safety and Efficacy of the 2.25-Mm Sirolimus-Eluting Bx Velocity Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions: The SIRIUS 2.25 Trial.” American Journal of Cardiology, vol. 98, no. 11, Dec. 2006, pp. 1455–60. EBSCOhost, https://doi.org/10.1016/j.amjcard.2006.06.047.

APA

Moses, J. W., Nikolsky, E., Mehran, R., Cambier, P. A., Bachinsky, W. B., Leya, F., Kuntz, R. E., Popma, J. J., Schleckser, P., Wang, H., Cohen, S. A., & Leon, M. B. (2006). Safety and Efficacy of the 2.25-mm Sirolimus-Eluting Bx Velocity Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions: the SIRIUS 2.25 Trial. American Journal of Cardiology, 98(11), 1455–1460. https://doi.org/10.1016/j.amjcard.2006.06.047

Chicago

Moses, Jeffrey W., Eugenia Nikolsky, Roxana Mehran, Patrick A. Cambier, William B. Bachinsky, Fred Leya, Richard E. Kuntz, et al. 2006. “Safety and Efficacy of the 2.25-Mm Sirolimus-Eluting Bx Velocity Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions: The SIRIUS 2.25 Trial.” American Journal of Cardiology 98 (11): 1455–60. doi:10.1016/j.amjcard.2006.06.047.